{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:11:30Z","timestamp":1790745090415,"version":"4.1.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology"],"published-print":{"date-parts":[[2012,9,18]]},"DOI":"10.1212\/wnl.0b013e31826aac73","type":"journal-article","created":{"date-parts":[[2012,9,6]],"date-time":"2012-09-06T20:27:24Z","timestamp":1346963244000},"page":"1259-1267","source":"Crossref","is-referenced-by-count":124,"title":["Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore"],"prefix":"10.1212","volume":"79","author":[{"given":"Di","family":"Dong","sequence":"first","affiliation":[{"name":"From the Health Services &amp; Systems Research Program (D.D., E.A.F.) and Emerging Infectious Diseases Program (C.S.), Duke-NUS Graduate Medical School, Singapore; Health Sciences Authority (C.S.), Singapore; and Global Health Institute (E.A.F.), Duke University, Durham, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Sung","sequence":"additional","affiliation":[{"name":"From the Health Services &amp; Systems Research Program (D.D., E.A.F.) and Emerging Infectious Diseases Program (C.S.), Duke-NUS Graduate Medical School, Singapore; Health Sciences Authority (C.S.), Singapore; and Global Health Institute (E.A.F.), Duke University, Durham, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Andrew","family":"Finkelstein","sequence":"additional","affiliation":[{"name":"From the Health Services &amp; Systems Research Program (D.D., E.A.F.) and Emerging Infectious Diseases Program (C.S.), Duke-NUS Graduate Medical School, Singapore; Health Sciences Authority (C.S.), Singapore; and Global Health Institute (E.A.F.), Duke University, Durham, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411103311906"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/428486a"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.09.162"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01022.x"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01719.x"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.57718"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04745.x"},{"key":"e_1_3_8_9_2","first-page":"15","article-title":"Association of HLA-B*1502 allele and carbamazepine-induced severe adverse cutaneous drug reaction among Asians, a review","volume":"13","author":"Lim KSS","year":"2008","unstructured":"Lim KSS, Kwan P, Chong TT . Association of HLA-B*1502 allele and carbamazepine-induced severe adverse cutaneous drug reaction among Asians, a review. Neurol Aisa 2008; 13: 15\u2013 21.","journal-title":"Neurol Aisa"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009717"},{"key":"e_1_3_8_11_2","unstructured":"US Food and Drug Administration. Information for healthcare professionals: dangerous or even fatal skin reactions: Carbamazepine (marketed as Carbatrol Equetro Tegretol and generics) [online]. Available at: www.fda.gov\/Drugs\/DrugSafety\/PostmarketdrugsafetyinformationforPatientsandProviders\/ucm124718.htm. Accessed June 18 2011."},{"key":"e_1_3_8_12_2","first-page":"CD001911","article-title":"Carbamazepine versus phenytoin monotherapy for epilepsy.","author":"Tudur Smith C","year":"2002","unstructured":"Tudur Smith C, Marson AG, Clough HE, Williamson PR . Carbamazepine versus phenytoin monotherapy for epilepsy. Cochrane Database Syst Rev 2002: CD001911.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_8_13_2","first-page":"77","article-title":"Pattern of anti-epileptic drug usage in a tertiary referral hospital in Singapore","volume":"2","author":"Lim SH","year":"1997","unstructured":"Lim SH, Tan EK, Chen C . Pattern of anti-epileptic drug usage in a tertiary referral hospital in Singapore. Neurol J Southeast Asia 1997; 2: 77\u2013 85.","journal-title":"Neurol J Southeast Asia"},{"key":"e_1_3_8_14_2","first-page":"CD001030","article-title":"Carbamazepine versus valproate monotherapy for epilepsy.","author":"Marson AG","year":"2000","unstructured":"Marson AG, Williamson PR, Hutton JL, Clough HE, Chadwick DW . Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database Syst Rev 2000: CD001030.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00585.x"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2003.00093.x"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh267"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2005.463010.x"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-003-0176-3"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.142.1.50"},{"key":"e_1_3_8_21_2","unstructured":"Singapore Health Sciences Authority. Serious adverse skin reactions associated with carbamazepine. Adverse Drug Reaction News Bulletin 2009 3 [online]. Available at: http:\/\/www.hsa.gov.sg\/publish\/hsaportal\/en\/health_products_regulation\/safety_information\/adr_bulletin.html. Accessed May 10 2011."},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0198-8859(01)00247-6"},{"key":"e_1_3_8_23_2","unstructured":"Singapore Department of Statistics. Census of population 2010. Statistical release 1: demographic characteristics education language and religion [online]. Available at: www.singstat.gov.sg\/pubn\/popn\/c2010sr1\/cop2010sr1.pdf. Accessed June 18 2011."},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.8.2.165"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209103271104"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.20801.x"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq1128"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.0b013e31826aac73","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T07:10:22Z","timestamp":1711523422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.0b013e31826aac73"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,18]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,9,18]]}},"alternative-id":["10.1212\/WNL.0b013e31826aac73"],"URL":"https:\/\/doi.org\/10.1212\/wnl.0b013e31826aac73","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,18]]}}}